- Home
- TRML
TRML
Tourmaline Bio Inc.
as 06-20-2025 4:00pm EST
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $49.33 | AVG Volume (30 days): | 282.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.56 - $29.79 | Next Earning Date: | 08-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 493.24% | Revenue Growth (next year): | N/A |
Latest Tourmaline Bio Inc. News
TRML Breaking Stock News: Dive into TRML Ticker-Specific Updates for Smart Investing
Insider Monkey
24 days ago
H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results
GlobeNewswire
a month ago
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease
GlobeNewswire
a month ago
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
GlobeNewswire
2 months ago
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
Simply Wall St.
2 months ago
Here's Why We're Not Too Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Situation
GlobeNewswire
3 months ago
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
TipRanks
4 months ago
Robinhood initiated, MongoDB downgraded: Wall Street’s top analyst calls
GlobeNewswire
4 months ago
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
Compare TRML vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRML Tourmaline Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.